Trial Profile
A Phase II pilot study to assess efficacy and safety of capecitabine and irinotecan plus bevacizumab followed by capecitabine and oxaliplatin plus bevacizumab or the reverse sequence in patients with metastatic colorectal cancer.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 28 Mar 2022
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Capecitabine (Primary) ; Irinotecan (Primary) ; Oxaliplatin (Primary)
- Indications Colon cancer; Colorectal cancer; Rectal cancer
- Focus Therapeutic Use
- Acronyms Passion
- 23 Sep 2019 Status changed from recruiting to completed.
- 21 Jan 2017 Results (n=80) assessing prognostic or predictive value of s-uPAR in front-line bevacizumab-treated metastatic colorectal cancer patients, presented at the 2017 Gastrointestinal Cancers Symposium
- 29 Nov 2016 New source (NCT02119026: ClinicalTrials.gov: US National Institutes of Health) found and integrated